Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Osteotech Tissue Recall Traced To Equipment Malfunction In Electrical Storm

This article was originally published in The Gray Sheet

Executive Summary

Osteotech is testing the rework procedure it developed to resterilize recalled and quarantined donor tissue and hopes to have the procedure validated and in place by year-end

You may also be interested in...



CDRH Examining CryoLife Heart Valve Risks Following Tissue Recall

CDRH is reviewing potential risks associated with CryoValve heart valves in the wake of an Aug. 14 recall order for CryoLife human tissue products

FDA Tissue Registration Rule Clarifies Classification Of Combination Devices

Manufacturers of combination devices incorporating human cells or tissues will have until Jan. 19, 2003 to register with FDA, according to a final rule released by the agency Jan. 18.

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Latest Headlines
See All
UsernamePublicRestriction

Register

MT017274

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel